Silent atrial fibrillation as a stroke risk factor and anticoagulation indication

Canadian Journal of Cardiology

Volumn 29, Issue 7 SUPPL, 2013, Pages

  Glotzer, Taya V ^a   Ziegler, Paul D ^b  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b MEDTRONIC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULATION; CARDIAC RESYNCHRONIZATION THERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); HEART ARRHYTHMIA; HEART ASSIST DEVICE; HEART ATRIUM FIBRILLATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; REVIEW; RISK FACTOR; THROMBOEMBOLISM;

EID: 84879546049     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.03.023     Document Type: Review

References (43)

1. Patten M., Maas R., Karim A., Müller H.W., Simonovsky R., Meinertz T. Event-recorder monitoring in the diagnosis of atrial fibrillation in symptomatic patients: subanalysis of the SOPAT trial. JCardiovasc Electrophysiol 2006, 17:1-5.
2. Hindricks G., Piorkowski C., Tanner H., et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation. Relevance of asymptomatic arrhythmia recurrence. Circulation 2005, 112:307-313.
3. Quirino G., Giammaria M., Corbucci G., et al. Diagnosis of paroxysmal atrial fibrillation in patients with implanted pacemakers: relationship to symptoms and other variables. Pacing Clin Electrophysiol 2009, 32:91-98.
4. Israel C.W., Gronefeld G., Ehrlich J.R., Li Y.G., Hohnloser S.H. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device. Implications for optimal patient care. JAm Coll Cardiol 2004, 43:47-52.
5. Page R.L., Wilkinson W.E., Clair W.K., McCarthy E.A., Pritchett E.L. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994, 89:224-227.
6. Strickberger S.A., Ip J., Saksena S., Curry K., Bahnson T.D., Ziegler P.D. Relationship between atrial tachyarrhythmias and symptoms. Heart Rhythm 2005, 2:125-131.
7. Senatore G., Stabile G., Bertaglia E., et al. Role of transtelephonic electro- cardiographic monitoring in detecting short-term arrhythmia recurrences after radiofrequency ablation in patients with atrial fibrillation. JAm Coll Cardiol 2005, 45:873-876.
8. Arya A., Piorkowski C., Sommer P., Kottkamp H., Hindricks G. Clinical implications of various follow up strategies after catheter ablation of atrial fibrillation. Pacing Clin Electrophysiol 2007, 30:458-462.
9. Hanke T., Charitos E.I., Stierle U., et al. Twenty-four-hour Holter monitor follow-up does not provide accurate heart rhythm status after surgical atrial fibrillation ablation therapy. Up to 12 months experience with a novel permanently implantable heart rhythm monitor device. Circulation 2009, 120:S177-S184.
10. Pokushalov E., Romanov A., Corbucci G., et al. Ablation of paroxysmal and persistent atrial fibrillation: 1-year follow-up through continuous subcutaneous monitoring. JCardiovasc Electrophysiol 2011, 22:369-375.
11. Ziegler P.D., Koehler J.L., Mehra R. Comparison of continuous versus intermittent monitoring of atrial arrhythmias. Heart Rhythm 2006, 3:1445-1452.
12. Fuster V., Rydén L.E., Cannom D.S., et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. JAm Coll Cardiol 2011, 57:e101-e198.
13. Savelieva I., Camm J. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. JInterv Card Electrophysiol 2000, 4:369-382.
14. Glotzer T.V., Hellkamp A.S., Zimmerman J., et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Sub-Study of MOST. Circulation 2003, 107:1614-1619.
15. Healey J.S., Martin J.L., Duncan A., et al. Pacemaker-detected atrial fibrillation in patients with pacemakers: prevalence, predictors, and current use of oral anticoagulation. Can J Cardiol 2013, 29:224-228.
16. Connolly S.J., Kerr C.R., Gent M., et al. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. NEngl J Med 2000, 342:1385-1391.
17. Lamas G.A., Lee K., Sweeney M., et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. NEngl J Med 2002, 346:1854-1862.
18. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.
19. Eckman M.H., Singer D.E., Rosand J., Greenberg S.M. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011, 4:14-21.
20. Orlov M.V., Ghali J.K., Araghi-Niknam M., Sherfesee L., Sahr D., Hettrick D.A. Asymptomatic atrial fibrillation in pacemaker recipients: incidence, progression, and determinants based on the atrial high rate trial. Pacing Clin Electrophysiol 2007, 30:404-411.
21. Capucci A., Santini M., Padeletti L., et al. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. JAm Coll Cardiol 2005, 46:1913-1920.
22. Glotzer T.V., Daoud E.G., Wyse D.G., et al. Rationale and design of a prospective study of the clinical significance of atrial arrhythmias detected by implanted device diagnostics: TRENDS. JInterv Card Electrophysiol 2006, 15:9-14.
23. Fuster V., Ryden L.E., Asinger A.W., et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. Circulation 2001, 104:2118-2150.
24. Glotzer T.V., Daoud E.G., Wyse D.G., et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS Study. Circ Arrhythmia Electrophysiol 2009, 2:474-480.
25. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
26. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010, 137:263-272.
27. Botto G.L., Padeletti L., Santini M., et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. JCardiovasc Electrophysiol 2009, 20:241-248.
28. 2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke 2011, 42:1768-1770.
29. Shanmugam N., Boerdlein A., Proff J., et al. Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure-cardiac resynchronization therapy population. Europace 2012, 14:230-237.
30. Healey J.S., Connolly S.J., Gold M.R., et al. Subclinical atrial fibrillation and the risk of stroke. NEngl J Med 2012, 366:120-129.
31. Hohnloser S.H., Capucci A., Fain E., et al. ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). Am Heart J 2006, 152:442-447.
32. Daoud E.G., Glotzer T.V., Wyse D.G., et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm 2011, 8:1416-1423.
33. Ziegler P.D., Glotzer T.V., Daoud E.G., et al. Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring in primary stroke prevention. Am J Cardiol 2012, 110:1309-1314.
34. Ziegler P.D., Glotzer T.V., Daoud E.G., et al. Incidence of newly detected atrial arrhythmias via implantable devices in patients with a prior history of thromboembolic events. Stroke 2010, 41:256-260.
35. Ip J., Waldo A.L., Lip G.Y., et al. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: rationale, design, and clinical characteristics of the initially enrolled cohort. The IMPACT study. Am Heart J 2009, 158:364-370.
36. Incidence of AF in high risk patients (REVEAL AF). Available at: Accessed February 18, 2013. http://www.clinicaltrials.gov/ct2/show/NCT01727297.
37. Prevalence of sub-clinical atrial fibrillation using an implantable cardiac monitor (ASSERT-II). Available at: Accessed February 18, 2013. http://www.clinicaltrials.gov/ct2/show/NCT01694394.
38. Sarkar S., Ritscher D., Mehra R. Adetector for a chronic implantable atrial tachyarrhythmia monitor. IEEE Trans Biomed Eng 2008, 55:1219-1224.
39. Purerfellner H., Gillis A.M., Holbrook R., Hettrick D.A. Accuracy of atrial tachyarrhythmia detection in implantable devices with arrhythmia therapies. Pacing Clin Electrophysiol 2004, 27:983-992.
40. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983-988.
41. Ogilvie I.M., Newton N., Welner S.A., Cowell W., Lip G.Y. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010, 123:638-645.
42. Friberg L., Hammar N., Ringh M., Pettersson H., Rosenqvist M. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Eur Heart J 2006, 27:1954-1964.
43. Boriani G., Santini M., Lunati M., et al. Improving thromboprophylaxis using atrial fibrillation diagnostic capabilities in implantable cardioverter-defibrillators: the multicentre Italian ANGELS of AF Project. Circ Cardiovasc Qual Outcomes 2012, 5:182-188.